Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

Share

.2020 Jun 8;10(1):9251.
doi: 10.1038/s41598-020-65849-6.

Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression

Affiliations

Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression

James M Brimson et al. Sci Rep..

Abstract

Sigma-1 and sigma-2 receptors are emerging therapeutic targets. We have identified that simple ammonium salts bind to these receptors and are effective in vivo. Radioligand binding assays were used to obtain structure-activity relationships of these salts. MTS assays were performed to determine their effect on growth in MCF7 and MDA-MB-486 cells. Anticancer properties were tested in NMRI mice transplanted with a fragment of mouse adenocarcinoma (MAC13). Antidepressant activity was tested using the forced-swim test and tail suspension tests. Dipentylammonium (Ki 43 nM), tripentylammonium (Ki 15 nM) and trihexylammonium (Ki 9 nM) showed high affinity for the sigma-1 receptor. Dioctanoylammonium had the highest affinity (K50 0.05 nM); this also showed the highest affinity for sigma-2 receptors (Ki 13 nM). Dipentylammonium was found to have antidepressant activity in vivo. Branched-chain ammonium salts showed lower affinity. Bis(2-ethylhexyl)ammonium (K50 29 µM), triisopentylammonium (K50 196 µM) and dioctanoylammonium showed a low Hill slope, and fitted a 2-site binding model for the sigma-1 receptor. We propose this two-site binding can be used to biochemically define a sigma-1 receptor antagonist. Bis(2-ethylhexyl)ammonium and triisopentylammonium were able to inhibit the growth of tumours in vivo. Cheap, simple ammonium salts act as sigma-1 receptor agonists and antagonists in vivo and require further investigation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any relationships that could be construed as a potential conflict of interest. Author DRF is employed by Eli Lilly. Author K.K.A. is employed by Ultragenyx Pharmaceuticals Inc.

Figures

Figure 1
Figure 1
Certain ammonium salt sigma-1 receptor ligands reduce cellular metabolism in MDA-MB-468 cells. Dioctylammonium (n = 4, filled circles), dicyclohexylammonium (n = 4, open circles), bis(2-ethylhexyl)ammonium (n = 6, filled squares) and triisopentylammonium (n = 6, open squares) reduced cellular activity in a concentration-dependent manner. Error bars show SEM. This figure is modified from the PhD thesis by J.M. Brimson.
Figure 2
Figure 2
Sigma-1 receptor siRNA hinders the ability of (a) bis(2-ethylhexyl)ammonium and (b) triisopentylammonium to reduce cellular metabolism in MDA-MB-468 cells. Levels of binding of 30 nM [³H] (+) pentazocine (c) are also shown. SiRNA targeting the sigma-1 receptor caused a shift in the pIC50 for bis(2-ethylhexyl)ammonium from 3.37 to 2.7 (P = 0.044, unpaired t-test), and for triisopentylammonium from 2.9 to 2.3 (P = 0.0095, unpaired t-test). Error bars show SEM, n = 3. SiRNA also caused a reduction in the sigma-1 receptor number, as monitored using a fixed concentration (30 nM) of [³H] (+) pentazocine (P < 0.0001, unpaired t-test, n = 8).This figure is reproduced from the PhD thesis by J.M. Brimson. Panel (c) has been previously presented.
Figure 3
Figure 3
The effect of dipentylammonium (DPA, 5 mg.kg−1) and sigma-1 receptor antagonist BD1047 (4 mg.kg−1) on despair behaviour in mice subjected to the forced-swim test. The control consisted of 10 ml.kg−1 saline; fluoxetine (10 mg.kg−1) was used as a positive control. Five mice were used for each data point. Error bars show SEM. ANOVA followed by Bonferronipost hoc multiple comparison gave: *control vs fluoxetine,P 0.0022; **control vs dipentylammonium,P < 0.0001; control vs BD1047,P = 0.13;##dipentylammonium vs BD1047 + dipentylammonium,P = 0.0001. This figure is reproduced from the PhD thesis by J.M. Brimson.
Figure 4
Figure 4
The effect of dipentylammonium (DPA, 5 mg.kg−1) and sigma-1 receptor antagonist BD1047 (4 mg.kg−1) on despair behaviour in mice subjected to the tail suspension test. The control consisted of an injection of 10 ml.kg−1 saline; fluoxetine (10 mg.kg−1) was used as a positive control. Ten mice were used for each data point, except BD1047 + dipentylammonium (n = 5). Error bars represent SEM. ANOVA followed by Bonferroni’spost hoc multiple comparison gave: **control vs fluoxetineP = 0.005, **control vs dipentylammonium,P = 0.0001; control vs BD1047 + dipentylammonium,P = 0.358; dipentylammonium vs BD1047 + dipentylammonium,P = 0.15. This figure is reproduced from the PhD thesis by J.M. Brimson.
Figure 5
Figure 5
The effects of dipentylammonium and triisopentylammonium on serotonin, dopamine and norepinepherine reuptake. (a) fluoxetine (open squares) dose-dependently prevents serotonin reuptake (IC50 83 nM), whereas dipentylammonium (open circles) and triisopentylammonium (closed squares) required a far higher concentration to prevent any serotonin uptake (IC50 1.1 mM and IC50 7.8 mM respectively). (b) GBR-12935 (open squares) inhibited dopamine transport with IC50 of 76 nM whereas dipentylammonium (open circles) and triisopentylammonium (closed squares) required a far higher concentration to prevent any dopamine uptake (IC50 0.6 mM and IC50 1.6 mM respectively). (c) Desipramine (open squares), potently inhibited norepinepherine (NE) reuptake with IC50 9 nM, whereas dipentylammonium (open circles) and triisopentylammonium (closed squares) required a far higher concentration to prevent any norepinepherine uptake (IC50 0.2 mM and IC50 7.8 mM respectively).
Figure 6
Figure 6
The effects of bis(2-ethylhexyl)ammonium and triisopentylammonium on metabolism of MAC13 cells in the MTS assay. Bis(2-ethylhexyl)ammonium (open circles) had a mean pIC50 of 5.3 ± 0.2, and triisopentylammonium (filled squares) had a mean pIC50 of 4.4 ± 0.2 from 6 independent assays. This figure is modified from the PhD thesis by J.M. Brimson.
Figure 7
Figure 7
The prevention of MAC13 tumour growthin vivo by bis(2-ethylhexyl)ammonium (open circles) and triisopentylammonium (filled squares) compared to vehicle treated mice (filled circles). Drug treatment commenced 12 days after implantation of the tumour. Error bars represent SEM from 6 mice.*Statistically significant tumour growth from day 12, determined using 2-way repeated measures ANOVA with Tukey’spost hoc test,P < 0.001.#Statistically significant reduction in tumour growth compared to the equivalent day of in the control,P < 0.001. This figure is modified from the PhD thesis by J.M. Brimson.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Martin WR, et al. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197:517–32. - PubMed
    1. Hanner M, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA. 1996;93:8072–7. - PMC - PubMed
    1. Schmidt HR, et al. Crystal structure of the human sigma1 receptor. Nature. 2016;532:527–30. - PMC - PubMed
    1. Fontanilla D, et al. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323:934–7. - PMC - PubMed
    1. Alon A, et al. Identification of the gene that codes for the sigma2 receptor. Proc Natl Acad Sci USA. 2017;114:7160–7165. - PMC - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp